Predictors of cancer-specific mortality after disease recurrence following radical cystectomy

BJU International

Volumn 111, Issue 3 B, 2013, Pages

  Rink, Michael ^a,b   Lee, Daniel J ^a   Kent, Matthew ^b   Xylinas, Evanguelos ^a,g   Fritsche, Hans Martin ^e   Babjuk, Marko ^h   Brisuda, Antonin ^h   Hansen, Jens ^d,i   Green, David A ^a   Aziz, Atiqullah ^e   Cha, Eugene K ^a   Novara, Giacomo ^j   Chun, Felix K ^d   Lotan, Yair ^c   Bastian, Patrick J ^f   Tilki, Derya ^f   Gontero, Paolo ^k   Pycha, Armin ^l   Baniel, Jack ^m   Mano, Roy ^m   Ficarra, Vincenzo ^j   Trinh, Quoc Dien ⁱ   Tagawa, Scott T ^a   Karakiewicz, Pierre I ⁱ   Scherr, Douglas S ^a   Sjoberg, Daniel D ^b   Shariat, Shahrokh F ^a   more..

^a Department of Obstetrics Gynecology   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g Paris Descartes University ^*  (France)

^h UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

ⁱ UNIVERSITÉ DE MONTRÉAL   (Canada)

^j UNIVERSITY OF PADOVA   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

^l General Hospital of Bolzano   (Italy)

^m RABIN MEDICAL CENTER   (Israel)

more..

Author keywords

bladder cancer; prognosis; recurrence; survival; urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; BLADDER CARCINOMA; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; FEMALE; HAZARD RATIO; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIVARIATE ANALYSIS; PATIENT COUNSELING; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEX DIFFERENCE;

AGED; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84874748000     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11433.x     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
2. Shariat SF, Karakiewicz PI, Palapattu GS, et al,. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-22
3. Stein JP, Lieskovsky G, Cote R, et al,. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75
4. Stenzl A, Cowan NC, De Santis M, et al,. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59: 1009-18
5. Madersbacher S, Hochreiter W, Burkhard F, et al,. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21: 690-6
6. Shariat SF, Karakiewicz PI, Palapattu GS, et al,. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006; 12: 6663-76
7. Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI,. Nomograms for bladder cancer. Eur Urol 2008; 54: 41-53
8. Karakiewicz PI, Shariat SF, Palapattu GS, et al,. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006; 176: 1354-62
9. Bochner BH, Kattan MW, Vora KC,. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24: 3967-72
10. Bajorin DF, Dodd PM, Mazumdar M, et al,. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-81
11. Mitra AP, Quinn DI, Dorff TB, et al,. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int 2012; 109: 846-54
12. Ploeg M, Kums AC, Aben KK, et al,. Prognostic factors for survival in patients with recurrence of muscle invasive bladder cancer after treatment with curative intent. Clin Genitourin Cancer 2011; 9: 14-21
13. von der Maase H, Sengelov L, Roberts JT, et al,. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-8
14. Novara G, Svatek RS, Karakiewicz PI, et al,. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 2010; 183: 2165-70
15. Lotan Y, Gupta A, Shariat SF, et al,. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 2005; 23: 6533-9
16. Shariat SF, Svatek RS, Tilki D, et al,. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 2010; 105: 1402-12
17. Rink M, Fajkovic H, Cha EK, et al,. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 2012; 61: 854-5
18. Sternberg CN, Donat SM, Bellmunt J, et al,. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007; 69: 62-79
19. Chromecki TF, Mauermann J, Cha EK, et al,. Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. World J Urol 2011 Oct 19; [Epub ahead of print]
20. Fajkovic H, Halpern JA, Cha EK, et al,. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011; 29: 457-63
21. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH,. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 2010; 105: 300-8
22. Nuhn P, May M, Sun M, et al,. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol 2012; 61: 58-64
23. Rink M, Shariat SF,. Can we apply nomograms derived in the United States to European patients? Yes, we can! Eur Urol 2012; 61: 65-6
24. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y,. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007; 109: 1106-13
25. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y,. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007; 20: 445-59
26. Rink M, Cha EK, Green D, et al,. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep 2012; 13: 122-35